Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Vistagen Therapeutics, Inc.(VTGN) Shareholders

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its Phase 3 PALISADE-3 trial of fasedienol, which did not meet its primary endpoint, leading to a significant stock price decline of over 80% [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between April 1, 2024, and December 16, 2025 [1]. - Defendants reportedly made positive statements while concealing adverse facts about the Phase 3 PALISADE-3 trial of fasedienol, which is intended for treating social anxiety disorder [2]. - Following the announcement that the trial did not show statistically significant improvement, Vistagen's stock plummeted from $4.36 to $0.86 per share, marking a decline of more than 80% [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until March 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4].